NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis $112.19 -1.50 (-1.32%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$112.02▼$116.5150-Day Range$100.57▼$120.5052-Week Range$43.89▼$121.90Volume435,535 shsAverage Volume700,902 shsMarket Capitalization$7.03 billionP/E RatioN/ADividend YieldN/APrice Target$116.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Blueprint Medicines alerts: Email Address Blueprint Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside3.7% Upside$116.33 Price TargetShort InterestBearish7.65% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 8 Articles This WeekInsider TradingSelling Shares$14.96 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.64) to ($2.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.60 out of 5 starsMedical Sector881st out of 936 stocksPharmaceutical Preparations Industry415th out of 436 stocks 2.3 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 9 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageBlueprint Medicines has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Blueprint Medicines' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.65% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Blueprint Medicines has recently increased by 5.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 2.4 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Blueprint Medicines this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,957,242.00 in company stock.Percentage Held by InsidersOnly 4.21% of the stock of Blueprint Medicines is held by insiders.Read more about Blueprint Medicines' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($4.64) to ($2.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -23.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -23.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 52.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Blueprint Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Blueprint Medicines Stock (NASDAQ:BPMC)Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More BPMC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMC Stock News HeadlinesJuly 10, 2024 | insidertrades.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 3,850 Shares of StockJuly 4, 2024 | insidertrades.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 333 Shares of StockJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 26, 2024 | insidertrades.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 74,034 Shares of StockJuly 26 at 9:45 PM | money.usnews.comBlueprint Medicines CorpJuly 25 at 5:26 AM | americanbankingnews.comBlueprint Medicines (BPMC) to Release Quarterly Earnings on ThursdayJuly 18, 2024 | prnewswire.comBlueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024July 17, 2024 | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Receives $116.33 Consensus Target Price from AnalystsJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 16, 2024 | seekingalpha.comBlueprint Medicines: Overdue For A BreatherMay 30, 2024 | prnewswire.comBlueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)May 26, 2024 | finance.yahoo.comBlueprint Medicines Corporation (BPMC)May 23, 2024 | prnewswire.comBlueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingMay 21, 2024 | finance.yahoo.comBlueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 yearMay 15, 2024 | msn.comStephens & Co. Initiates Coverage of Blueprint Medicines (BPMC) with Overweight RecommendationMay 14, 2024 | msn.comBlueprint Medicines started at buy by Stephens, citing Ayvakit franchiseMay 14, 2024 | markets.businessinsider.comUnveiling 18 Analyst Insights On Blueprint MedicinesMay 9, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)See More Headlines Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees655Year Founded2011Price Target and Rating Average Stock Price Target$116.33 High Stock Price Target$168.00 Low Stock Price Target$75.00 Potential Upside/Downside+3.6%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($4.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-506,980,000.00 Net Margins-102.15% Pretax Margin-101.93% Return on Equity-193.48% Return on Assets-42.98% Debt Debt-to-Equity Ratio0.67 Current Ratio3.76 Quick Ratio3.61 Sales & Book Value Annual Sales$249.38 million Price / Sales28.19 Cash FlowN/A Price / Cash FlowN/A Book Value$2.15 per share Price / Book52.21Miscellaneous Outstanding Shares62,620,000Free Float59,981,000Market Cap$7.03 billion OptionableOptionable Beta0.63 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Kathryn Haviland (Age 48)President, CEO & Director Comp: $1.17MMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Director Comp: $50kMr. Michael Landsittel (Age 52)Chief Financial Officer Comp: $785.36kMs. Tracey L. McCain Esq. (Age 56)Executive VP, Chief Legal & Compliance Officer and Secretary Comp: $764.9kDr. Fouad Namouni M.D. (Age 55)President of Research & Development Comp: $916.4kMs. Ariel Hurley (Age 50)Senior VP, Finance & Principal Accounting Officer Dr. Christopher K. Murray Ph.D. (Age 60)Senior VP of Technical Operations and Chief Technical Operations & Quality Officer Comp: $338.37kDr. Percy H. Carter M.B.A. (Age 53)Ph.D., Chief Scientific Officer Comp: $761.15kJenna CohenSenior Director & Head of Investor RelationsMs. Debra Durso-Bumpus (Age 54)Chief People Officer More ExecutivesKey CompetitorsForty SevenNASDAQ:FTSVTurning Point TherapeuticsNASDAQ:TPTXCelldex TherapeuticsNASDAQ:CLDXDeciphera PharmaceuticalsNASDAQ:DCPHSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 32,740 shares on 7/26/2024Ownership: 0.437%EFG Asset Management North America Corp.Bought 132 shares on 7/26/2024Ownership: 0.045%Legato Capital Management LLCBought 5,165 shares on 7/26/2024Ownership: 0.008%Calamos Advisors LLCSold 1,134 shares on 7/25/2024Ownership: 0.011%Pallas Capital Advisors LLCBought 252 shares on 7/22/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions BPMC Stock Analysis - Frequently Asked Questions How have BPMC shares performed this year? Blueprint Medicines' stock was trading at $92.24 on January 1st, 2024. Since then, BPMC shares have increased by 21.6% and is now trading at $112.19. View the best growth stocks for 2024 here. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) announced its quarterly earnings data on Thursday, May, 2nd. The biotechnology company reported ($1.32) earnings per share for the quarter, topping analysts' consensus estimates of ($1.64) by $0.32. The biotechnology company had revenue of $96.12 million for the quarter, compared to analysts' expectations of $82.58 million. Blueprint Medicines had a negative net margin of 102.15% and a negative trailing twelve-month return on equity of 193.48%. What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Top institutional investors of Blueprint Medicines include Bank of New York Mellon Corp (0.44%), Assenagon Asset Management S.A. (0.26%), EFG Asset Management North America Corp. (0.04%) and Harbor Capital Advisors Inc. (0.04%). Insiders that own company stock include Jeffrey W Albers, Kate Haviland, Christina Rossi, Fouad Namouni, Tracey L Mccain, Michael Landsittel, Debra Durso-Bumpus, Percy H Carter, Christopher K Murray, L Becker Hewes, Ariel Hurley, George Demetri and Mark Alan Goldberg. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD) and QUALCOMM (QCOM). This page (NASDAQ:BPMC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
